BEYOND TITER: Identify Top Producers with Favorable Product Quality Attributes within 5 Days of Cloning
CHO cell line selection is a painful bottleneck in biotherapeutic development, particularly for complex molecules like bispecifics. The Opto® CLD workflow on the Beacon® system accelerates early CLD by integrating high throughput cell sorting, cloning, culture, productivity, growth, and product quality assays into a single, 5-day automated process. Hear about capabilities of on-chip detection that pinpoints best clones early on.
Cell Line Development (CLD) on the Beacon® optofluidic system enables high throughput cloning, screening, and selection of top-performing CHO cell lines in just days. Used globally by leading pharmaceutical companies and CDMOs, the Beacon® system’s industry-leading technology delivers unrivaled speed and efficiency to cell line development workflows. The Opto® CLD workflow has enabled customers to select clones with higher titers than traditional methods (Customer Spotlight: Catalent), increase throughput by 4X while reducing their cell line development timeline by up to 50% (Customer Spotlight: Mycenax), and recover clones with >99% monoclonality assurance to support FDA IND regulatory filings (Application Note: FDA Accepted IND). In addition, the Opto™ Assure quality assays enable users to select clones with favorable product quality attributes within 5 days of cloning to reduce overall costs, improve the probability of success, and further shorten timelines by selecting top clones for scale up.
Set your IND up for success by getting FDA-accepted monoclonality assurance in just days.
See how our customers apply our CLD workflow to streamline cell line development and get to the clinic faster.
Replace 8-12 weeks of challenging well plate steps with Opto® CLD on the Beacon® optofluidic system.
Screen thousands of clones in parallel and select top clones for even non-traditional antibody molecules, like bi-specifics.
Get to production faster with Opto™ Assure for early manufacturability assessment.
Opto™ Assure minimizes risk of costly late stage failures by identifying clones early on that secrete product with high yield and desired quality. Opto Assure assay for aggregation enables direct detection of product aggregates within days of single cell cloning. This lets you confidently identify and select clones that secrete high-quality complex molecules and develop better production cell lines faster.
The Berkeley Lights Opto CLD workflow enables in-line controls to measure clonality during clone recovery. After recovery of each clone, media is flushed into “blank” wells to detect any residual cells. Expand >90% of selected clones from the Beacon system when recovered into 96-well plates, with >99% monoclonality assurance – which is equivalent to four rounds of limiting dilution!
Access to more relevant cell diversity with Selective Cell Cloning.
Selective Cell Cloning with Opto CLD lets you screen up to 100,000 cells in a single 5-day workflow, enabling access to more relevant cell diversity than conventional methods for cell line development. Gently enrich transfected pools by identifying and cloning only cells that are viable and express your protein of interest. With Selective Cell Cloning, you can eliminate weeks of mini-pool processing by enabling deeper screening of bulk stable pools.
The Beacon system’s optofluidic chip technology and integrated imaging provide direct evidence of >99% monoclonality, without manual effort and uncertainty of traditional methods. Learn how the Opto CLD workflow provides superior cloning technology and in-process quality controls for definitive evidence of monoclonality to support regulatory approvals.
Spotlight assay: Simultaneous, quantitative antibody titer measurements on thousands of clones (LEFT). Clones selected based on titer measurements on the Beacon system had 1.5–3-fold higher titers than clones selected using traditional clone picking technology when scaled up to shake flask fed-batch cultures (RIGHT). ©2019 Catalent, Inc. All rights reserved.
Find out how the Opto CLD workflow sets a new standard for quality, capacity, and speed in cell line development to let BioPharma get more molecules to the clinic faster.
Find our how the Opto CLD workflow sets a new standard for quality, capacity, and speed in cell line development and allows CDMOs to scale operations and drive new business.
Dr. James Rothman, Nobel Laureate hosts an in-depth discussion with distinguished guests, Dr. Jennitte Stevens from Amgen, Dr. Gregory Bleck from Catalent-Biologics, and Dr. Trent Munro from the University of Queensland on fast-tracking the development of therapeutic antibodies and vaccines for SARS-CoV-2.